synthes
character
seri
compound
contain
undecan
scaffold
design
analog
amantadin
inhibitor
proton
channel
influenza
viru
inhibit
wildtyp
wt
channel
amantadineresist
mutant
ion
channel
measur
xenopu
oocyt
use
twoelectrod
voltag
clamp
tev
assay
novel
compound
inhibit
wt
ion
channel
low
micromolar
rang
note
sever
compound
inhibit
mutant
ion
channel
one
submicromolar
ic
none
compound
found
inhibit
mutant
ion
channel
antivir
activ
three
novel
dual
wt
channel
inhibitor
confirm
influenza
viru
yield
assay
amantadin
cage
compound
influenza
viru
proton
channel
drug
design
c
mcc
minimum
cytotox
concentr
concentr
produc
minim
alter
cell
morpholog
hr
incub
compound
cc
cytotox
concentr
determin
mt
cell
viabil
test
valu
shown
mean
determin
j
med
chem
influenza
viru
protein
residu
long
integr
membran
protein
transmembran
tm
domain
residu
small
ectodomain
residu
residu
long
cytoplasm
tail
protein
encod
splice
mrna
deriv
viral
rna
segment
proton
channel
activ
requir
viral
replic
influenza
viru
particl
enter
host
cell
endocytosi
mainli
via
clathrinmedi
rout
within
endosom
releas
viral
ribonucleoprotein
rnp
complex
matrix
protein
depend
acidif
viral
interior
lower
ph
accomplish
proton
channel
facilit
flow
proton
acid
endosom
lumen
interior
virion
proton
channel
function
found
essenti
influenza
subtyp
thu
far
studi
viru
strain
eg
fowl
plagu
viru
protein
also
equilibr
ph
transgolgi
network
prevent
prematur
conform
chang
viral
hemagglutinin
ha
influenza
virus
import
pathogen
capabl
caus
signific
morbid
mortal
human
two
class
antivir
drug
current
avail
ion
channel
inhibitor
amantadin
amt
rimantadin
neuraminidas
na
inhibitor
oseltamivir
zanamivir
howev
use
amt
rimantadin
drop
sharpli
recent
year
due
widespread
resist
virus
prompt
center
diseas
control
recommend
discontinu
use
amtbas
drug
also
resist
oseltamivir
frequent
observ
recent
flu
season
therefor
urgent
need
develop
next
gener
antivir
drug
activ
drugresist
influenza
virus
systemat
mutat
analysi
porelin
residu
tm
domain
identifi
mani
amtresist
mutat
howev
mutat
ie
observ
transmiss
virus
mutat
frequent
occur
amtresist
mutat
channel
properti
ion
select
activ
mutant
appear
similar
wt
channel
suggest
channel
properti
need
fine
tune
order
viru
transmiss
mani
effort
made
discov
new
small
molecular
inhibitor
amtresist
mutant
form
exampl
wang
et
al
report
sever
spiro
compound
spiroadamantan
inhibit
mutant
good
efficaci
electrophysiolog
viru
plaqu
reduct
assay
recent
group
also
discov
new
compound
inhibit
preval
drugresist
mutant
chart
studi
report
novel
scaffold
design
inhibit
channel
sever
pyrrolidin
deriv
found
inhibit
wt
channel
well
mutant
ion
channel
best
compound
guanidin
low
micromolar
activ
wt
channel
ic
submicromolar
activ
mutant
ic
past
year
group
synthes
sever
polycycl
amt
analog
contain
differ
scaffold
includ
ringcontract
ringrearrang
deriv
amt
chart
sever
ringcontract
analog
amt
amin
evalu
inhibit
proton
channel
activ
use
conduct
assay
oocyt
display
similar
ic
valu
wt
amt
unfortun
inact
amtresist
mutant
form
also
explor
activ
larger
ringrearrang
analog
amt
use
pentacyclo
dodecan
scaffold
interestingli
primari
amin
sever
deriv
includ
secondari
tertiari
amin
amidin
guanidin
inhibit
proton
channel
activ
conform
rigid
pyrrolidinebas
deriv
show
promis
activ
wt
channel
slightli
less
activ
amt
moreov
primari
amin
show
activ
mutant
form
pyrrolidin
deriv
show
margin
activ
mutant
tabl
base
promis
result
reason
synthesi
pyrrolidin
analog
alreadi
activ
bisnoradamantan
featur
unpreced
undecan
ring
may
lead
compound
higher
activ
wt
mutant
reaction
known
diacid
b
urea
minut
yield
imid
b
subsequ
reduc
give
secondari
amin
b
good
overal
yield
reduct
alkyl
secondari
amin
formaldehyd
nacnbh
led
correspond
tertiari
amin
b
good
yield
take
account
observ
correspond
guanidin
deriv
previous
synthes
amin
also
inhibitor
channel
synthes
guanidin
b
amin
b
monohydrochlorid
scheme
recent
experiment
comput
studi
shown
mutat
residu
smaller
side
chain
alanin
mutant
destroy
hydrophob
gate
form
residu
increas
pore
radiu
ntermin
end
amin
guanidin
display
higher
inhibitori
activ
mutant
channel
correspond
smaller
analog
see
also
sinc
recent
md
calcul
suggest
larger
hydrophob
molecul
may
fill
pore
mutant
better
design
two
novel
larger
analog
dual
inhibitor
ie
synthesi
pyrrolidin
follow
rout
outlin
scheme
novel
diacid
deriv
requir
thu
synthes
diacid
easili
avail
diketon
follow
synthet
sequenc
shown
scheme
previous
develop
relat
bisnoradamantan
deriv
homolog
diketon
transform
mixtur
correspond
bisvinyl
iodid
synand
via
correspond
bishydrazon
follow
barton
procedur
respect
overal
yield
palladium
catalyz
methoxycarbonyl
afford
yield
respect
mixtur
syn
anti
regioisom
catalyt
hydrogen
pd
c
mixtur
synand
gave
stereoisomer
mixtur
diester
yield
respect
reaction
diester
two
equival
lihmd
anhydr
thf
follow
reaction
correspond
bisenol
one
equival
iodin
gave
yield
respect
final
hydrolysi
diester
gave
diacid
yield
respect
scheme
diacid
follow
synthet
sequenc
shown
scheme
prepar
amin
guanidin
good
overal
yield
see
support
inform
detail
pharmacolog
evalu
compound
fulli
character
salt
hydrochlorid
tartrat
spectroscop
data
element
analys
inhibitori
activ
compound
test
channel
express
xenopu
oocyt
use
tev
techniqu
inhibitor
initi
test
inhibit
wt
channel
activ
chosen
measur
inhibitori
concentr
ic
result
given
tabl
amt
inhibit
wt
channel
ic
isochron
min
inhibit
assay
suggest
design
amt
analog
pyrrolidin
piperidin
deriv
may
result
favor
orient
insid
channel
pore
compar
freeli
rotat
alkylamin
chain
thu
previous
test
tetracycl
deriv
conform
rigid
amin
tabl
sharp
contrast
poor
perform
primari
amin
dien
shown
abl
inhibit
wt
channel
show
ic
biscyclopropan
slightli
increas
potenc
sinc
deriv
show
ic
interestingli
concentr
inhibit
channel
activ
superior
amt
yet
much
less
base
result
synthes
compound
conform
rigid
analog
agreement
previou
trend
observ
go
pyrrolidin
potent
inhibitor
wt
channel
ic
respect
interestingli
better
inhibitor
mutant
channel
guanidin
show
ic
alkyl
reduc
inhibitori
potenc
wt
mutant
also
synthes
smaller
larger
analog
expect
go
smaller
analog
import
reduct
activ
mutant
observ
although
compound
kept
inhibitori
activ
wt
tertiari
amin
less
potent
correspond
secondari
amin
reason
tertiari
amin
synthes
go
dimethyl
deriv
correspond
diethyl
deriv
activ
wt
mutant
channel
diminish
probabl
freeli
rotat
ethyl
chain
make
destabil
contact
backbon
protein
contact
evid
narrow
wt
channel
reflect
lower
inhibitori
activ
wt
channel
compar
conform
rigid
amin
guanidin
low
micromolar
inhibitori
activ
wt
channel
restor
pleasingli
good
inhibit
mutant
channel
observ
show
ic
determin
bind
affin
class
compound
chose
one
potent
inhibitor
wt
measur
affin
solut
nmr
drug
titrat
peptid
span
transmembran
domain
design
reconstitut
dodecylphosphocholin
dpc
micel
peptid
deterg
ratio
condit
form
tetram
predominantli
titrat
solut
characterist
peak
h
monitor
hnmr
figur
found
drugbound
form
slow
exchang
apoform
new
peak
ppm
correspond
h
emerg
upon
drug
addit
continu
increas
drug
titrat
peak
ppm
associ
apoform
becom
weaker
previous
observ
peak
correl
bind
drug
pore
channel
plot
peak
integr
ppm
increas
drug
concentr
shown
figur
data
fit
use
nonlinear
leastsquar
fit
equat
describ
earlier
best
fit
gave
stoichiometri
ratio
drug
per
tetram
dissoci
constant
k
note
titrat
conduct
protein
concentr
mm
significantli
k
thu
actual
k
difficult
determin
howev
theoret
curv
fit
fix
stoichiometri
mean
one
drug
per
tetram
bind
differ
k
show
k
significantli
less
see
figur
worth
note
differ
ic
k
reflect
differ
experiment
assay
use
determin
properti
long
known
channel
blocker
slow
binder
note
second
order
rate
constant
amantadin
ie
udorn
strain
ic
depend
amount
time
drug
expos
target
novel
compound
subject
antivir
evalu
wide
rang
dna
rna
virus
use
cpe
reduct
assay
relev
cell
line
none
compound
display
activ
envelop
dna
virus
herp
simplex
viru
type
type
vaccinia
viru
envelop
rna
virus
felin
coronaviru
viru
respiratori
syncyti
viru
vesicular
stomat
viru
sindbi
viru
punta
toro
viru
nonenvelop
rna
virus
coxsackieviru
data
shown
basic
cpe
reduct
assay
influenza
viru
perform
mdck
cell
cultur
three
viru
strain
use
strain
viru
two
amantadineresist
mutat
protein
strain
wt
protein
strain
antivir
data
obtain
microscop
score
virusinduc
cpe
confirm
colorimetr
mt
cell
viabil
assay
parallel
compound
appli
uninfect
mdck
cell
estim
cytotox
microscopi
mt
cell
viabil
assay
tabl
agreement
tev
assay
see
compound
activ
amantadineresist
strain
carri
mutat
compound
amt
correl
seen
cell
cultur
activ
viru
ec
valu
ic
valu
wt
proton
channel
function
howev
case
amin
guanidin
b
four
compound
quit
pronounc
cytotox
mdck
cell
threeday
cpe
reduct
assay
ie
minimum
cytotox
concentr
lower
may
mask
potenti
inhibitori
effect
compound
toward
viru
tabl
difficult
specul
caus
toxic
amphiphil
compound
might
well
caus
membran
disrupt
effect
given
suffici
time
exposur
cpe
test
assay
henc
compound
may
display
toxic
effect
make
imposs
assess
potenti
antivir
effect
hand
compound
favor
activ
select
easili
identifi
cpe
assay
ie
therefor
evalu
amin
guanidin
b
viru
yield
assay
strain
carri
wt
viru
releas
supernat
hour
infect
quantifi
realtim
rtpcr
shown
tabl
amin
guanidin
ec
valu
ie
concentr
caus
reduct
viru
yield
order
magnitud
valu
note
amt
rimantadin
amt
abl
afford
reduct
viru
yield
ec
valu
present
work
show
start
compound
activ
wt
channel
possibl
design
compound
activ
wt
mutant
channel
fact
inhibit
channel
effect
amantadin
inhibit
wt
low
micromolar
antivir
activ
three
dual
inhibitor
identifi
amin
guanidin
confirm
influenza
viru
yield
assay
interestingli
compound
report
first
exampl
nonadamantan
deriv
endow
low
micromolar
activ
mutant
channel
open
way
design
novel
inhibitor
structur
base
nonadamantan
scaffold
take
account
broad
util
adamantan
scaffold
medicin
chemistri
novel
azapolycycl
ring
report
may
interest
therapeut
area
adamantan
deriv
medicin
interest
cdna
encod
influenza
insert
vector
express
oocyt
plasma
membran
mutant
gener
quikchang
sitedirect
mutagenesi
kit
agil
technolog
synthesi
mrna
microinject
oocyt
describ
previous
macroscop
membran
current
record
hour
inject
describ
previous
test
compound
appli
ph
variou
concentr
inward
current
reach
maximum
compound
appli
min
residu
membran
current
compar
membran
current
applic
compound
membran
current
analyz
pclamp
softwar
packag
axon
instrument
sunnyval
ca
peptid
correspond
transmembran
domain
udorn
ssdplvvaasiigilhlilwildrl
synthes
use
optim
protocol
describ
nmr
sampl
prepar
start
mix
peptid
dpc
desir
molar
ratio
ethanol
follow
remov
ethanol
nitrogen
flush
lyphil
ensur
complet
remov
result
film
dissolv
nmr
buffer
consist
mm
sodium
phosphat
h
ph
drug
dissolv
h
ad
nmr
sampl
gradual
final
dilut
less
antivir
activ
compound
determin
establish
cpe
reduct
assay
use
divers
set
dna
rna
virus
indic
includ
three
sub
type
influenza
viru
apuerto
ahong
bhong
briefli
madindarbi
canin
kidney
cell
seed
plate
expos
influenza
viru
multipl
infect
ccid
cell
cultur
infect
dose
per
well
togeth
test
compound
three
day
incub
microscopi
perform
score
virusinduc
cytopath
effect
cpe
well
compound
cytotox
data
confirm
colorimetr
formazanbas
mt
cell
viabil
assay
antivir
activ
express
ec
valu
compound
concentr
produc
inhibit
virusinduc
cpe
determin
microscopi
mt
assay
compound
cytotox
express
minimum
inhibitori
concentr
mcc
ie
concentr
produc
minim
chang
cell
morpholog
cc
valu
ie
concentr
caus
reduct
cell
viabil
mt
assay
determin
effect
compound
viru
yield
mdck
cell
incub
influenza
viru
strain
compound
hr
incub
supernat
collect
frozen
viru
releas
supernat
quantifi
realtim
qrtpcr
describ
antivir
activ
express
ec
ec
valu
ie
compound
concentr
produc
viru
yield
reduct
log
log
respect
melt
point
determin
open
capillari
tube
mfb
gallenkamp
melt
point
apparatu
mhz
mhz
c
nmr
spectra
mhz
mhz
c
nmr
spectra
mhz
h
nmr
spectra
record
varian
gemini
varian
mercuri
varian
inova
spectromet
respect
chemic
shift
report
ppm
scale
rel
intern
tetramethylsilan
coupl
constant
report
hertz
hz
assign
given
nmr
spectra
new
compound
carri
basi
dept
cosi
h
h
standard
procedur
cosi
h
c
ghsqc
ghmbc
sequenc
experi
asterisk
nmr
data
mean
interchang
signal
ir
spectra
run
perkinelm
spectrum
rx
spectrophotomet
absorpt
valu
express
wavenumb
cm
signific
absorpt
band
given
gcm
analysi
carri
inert
agil
technolog
ga
chromatograph
equip
agil
mm
capillari
column
stationari
phase
phenylmethylsilicon
diphenyl
dimethylpolysiloxan
use
follow
condit
initi
temperatur
min
mmol
urea
g
puriti
mmol
heat
slowli
mixtur
melt
heat
min
cool
water
ml
ad
suspens
extract
ch
cl
ml
combin
organ
extract
wash
brine
ml
dri
anhydr
na
filter
concentr
vacuo
dryness
give
imid
white
solid
g
yield
analyt
sampl
obtain
crystal
chcl
mmol
acetonitril
ml
nabh
cn
content
g
mmol
acoh
ml
formaldehyd
aqueou
solut
ml
mmol
ad
mixtur
magnet
stir
room
temperatur
h
nabh
cn
content
g
mmol
formaldehyd
aqueou
solut
ml
mmol
ad
stir
room
temperatur
continu
h
mixtur
concentr
vacuo
residu
suspend
water
ml
solut
made
basic
aqueou
solut
n
naoh
ml
extract
etoac
ml
combin
organ
extract
dri
anhydr
na
filter
treat
excess
ether
solut
hcl
concentr
vacuo
give
hydrochlorid
g
yield
white
solid
analyt
sampl
obtain
crystal
mp
dec
ir
kbr
undecan
hydrochlorid
suspens
g
mmol
et
n
ml
mmol
hydrochlorid
g
mmol
ch
cn
ml
heat
h
suspens
allow
stand
overnight
freezer
solid
separ
filtrat
vacuo
wash
diethyl
ether
give
beig
solid
mg
yield
mp
dec
ir
kbr
mmol
anhydr
thf
ml
lialh
g
mmol
ad
portionwis
addit
finish
solut
heat
reflux
h
mixtur
cool
icewat
bath
treat
n
aq
solut
naoh
til
basic
ph
ml
stir
room
temperatur
h
mixtur
filter
celit
filtrat
thoroughli
wash
ch
cl
organ
layer
separ
dri
anhydr
na
filter
evapor
vacuo
obtain
solid
residu
dissolv
et
ml
treat
excess
hcl
et
give
hydrochlorid
g
yield
analyt
sampl
obtain
white
solid
crystal
meohet
mmol
acetonitril
ml
nabh
cn
content
g
mmol
acoh
ml
formaldehyd
aqueou
solut
ml
mmol
ad
mixtur
magnet
stir
room
temperatur
h
nabh
cn
content
g
mmol
formaldehyd
aqueou
solut
ml
mmol
ad
stir
room
temperatur
continu
h
mixtur
concentr
vacuo
residu
suspend
water
ml
solut
made
basic
aqueou
solut
n
naoh
ml
extract
etoac
ml
combin
organ
extract
dri
anhydr
na
filter
treat
excess
ether
solut
hcl
concentr
vacuo
give
hydrochlorid
g
yield
white
solid
analyt
sampl
obtain
crystal
meohet
mp
dec
ir
kbr
mmol
anhydr
toluen
ml
sodium
bi
aluminium
hydrid
ml
solut
toluen
mmol
ad
dropwis
addit
finish
solut
heat
reflux
h
mixtur
cool
icewat
bath
treat
aq
solut
koh
til
basic
ph
stir
room
temperatur
h
organ
layer
separ
aqueou
one
extract
ch
cl
ml
combin
organ
layer
dri
anhydr
na
filter
evapor
vacuo
give
amin
orang
oil
mg
amin
dissolv
methanol
ml
treat
tartar
acid
mg
mmol
dissolv
minimum
amount
methanol
mixtur
concentr
vacuo
yield
tartrat
yellow
solid
mg
yield
analyt
sampl
tartrat
obtain
crystal
meohet
mp
ir
kbr
bind
affin
wt
determin
solut
nmr
drug
titrat
normal
peak
volum
h
drugbound
form
plot
function
concentr
fit
yield
stoichiometri
ratio
drugtetram
k
curv
shown
blue
comparison
theoret
curv
fit
fix
stoichiometri
k
shown
red
green
pink
respect
detail
curv
fit
found
support
inform
synthesi
polycycl
pyrrolidin
deriv
synthesi
diester
structur
amantadin
rimantadin
recent
develop
analog
potent
activ
mutant
channel
ic
valu
shown
report
inhibitori
concentr
obtain
tev
assay
chart
structur
known
ringcontract
ringrearrang
analog
amantadin
tabl
inhibitori
effect
synthes
compound
wt
proton
channel
function
